Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data from their Phase 1/2a study on a melanoma treatment yielded mixed results. Analysts and investors reacted to the company’s announcement that lower doses of the radiopharmaceutical [212Pb]VMT01 were more effective compared to higher doses, while an unexpected […]
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). The trial evaluated the subcutaneous formulation of PD-1 immune checkpoint inhibitor Opdivo (nivolumab), co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20), referred to as […]
The US Food and Drug Administration (FDA) has approved the combination of Bristol Myers Squibb’ Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) as a first line therapy for advanced renal cell carcinoma (RCC), a type of kidney cancer. As per the FDA approval, Opdivo 240mg has to be injected intravenously every two weeks or 480mg every […]
OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]
Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in adults. The approval of the programmed death-1 (PD-1) immune checkpoint inhibitor is for patients who were previously subjected […]
Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). The approval is for the Opdivo/Yervoy combination to be used with two cycles of platinum-based chemotherapy in adult patients, whose tumors have no sensitizing epidermal growth […]
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) in adults. The approval is for Opdivo 360 mg every three weeks with 1 mg/kg every six weeks (injections for intravenous use) of […]
Bristol Myers Squibb has secured approval for the combination of Opdivo (nivolumab) 1 mg/kg and Yervoy (ipilimumab) 3 mg/kg from the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC) in patients who were previously treated with sorafenib. Approval for the indication has been issued under accelerated approval on the basis […]
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate -331 trial, designed to assess its effectiveness in small cell lung cancer (SCLC) patients whose condition had relapsed after platinum-based chemotherapy. The trial results reveal that Opdivo did not significantly enhance overall survival compared to the current […]
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with Compugen’s COM701 in the treatment of advanced solid tumors. This collaboration will evaluate the combination of COM701, an anti-PVRIG antibody under investigation by Compugen, with Opdivo, a programmed death-1 (PD-1) […]